Cargando…
Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience
Objectives: Remdesivir is currently approved for the treatment of COVID-19. The recommendation for using remdesivir in patients with COVID-19 was based on the in vitro and in vivo activity of this drug against SARS-CoV-2. Methods: This was a prospective observational study conducted on a population...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432083/ https://www.ncbi.nlm.nih.gov/pubmed/34501233 http://dx.doi.org/10.3390/jcm10173784 |
_version_ | 1783751081661038592 |
---|---|
author | Russo, Alessandro Binetti, Erica Borrazzo, Cristian Cacciola, Elio Gentilini Battistini, Luigi Ceccarelli, Giancarlo Mastroianni, Claudio Maria d’Ettorre, Gabriella |
author_facet | Russo, Alessandro Binetti, Erica Borrazzo, Cristian Cacciola, Elio Gentilini Battistini, Luigi Ceccarelli, Giancarlo Mastroianni, Claudio Maria d’Ettorre, Gabriella |
author_sort | Russo, Alessandro |
collection | PubMed |
description | Objectives: Remdesivir is currently approved for the treatment of COVID-19. The recommendation for using remdesivir in patients with COVID-19 was based on the in vitro and in vivo activity of this drug against SARS-CoV-2. Methods: This was a prospective observational study conducted on a population of patients hospitalized for COVID-19. The primary endpoint of this study was the impact of remdesivir-containing therapy on 30-day mortality; the secondary endpoint was the impact of remdesivir-containing therapy on the need for high-flow oxygen therapy (HFNC), non-invasive ventilation (NIV), or mechanical ventilation. The data were analyzed after propensity score matching. Results: A total of 407 patients with SARS-CoV-2 pneumonia were consecutively enrolled. Out of these, 294 (72.2%) were treated with remdesivir and 113 (27.8%) were not. Overall, 61 patients (14.9%) were treated during hospitalization with HFNC, NIV, or mechanical ventilation, while 30-day mortality was observed in 21 patients (5.2%). Univariate analysis of patients treated with remdesivir or not showed no differences in 30-day mortality (4% vs. 6%, p = 0.411) in the two study groups. Cox regression analysis, after propensity score matching, showed that therapies, including remdesivir-containing therapy, were not statistically associated with 30-day survival or mortality. The Kaplan–Meier curves of 30-day survival in patients treated with remdesivir or not before (p = 0.24) and after (p = 0.88) propensity score matching showed no differences between the two study groups. Finally, patients treated with remdesivir or not showed the same need for HFNC/NIV or mechanical ventilation. Conclusions: This real-life experience of remdesivir use in hospitalized patients with COVID-19 was not associated with significant increases in rates of survival or reduced use of HFNC/NIV or mechanical ventilation compared with patients treated with other therapies not including remdesivir. |
format | Online Article Text |
id | pubmed-8432083 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84320832021-09-11 Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience Russo, Alessandro Binetti, Erica Borrazzo, Cristian Cacciola, Elio Gentilini Battistini, Luigi Ceccarelli, Giancarlo Mastroianni, Claudio Maria d’Ettorre, Gabriella J Clin Med Article Objectives: Remdesivir is currently approved for the treatment of COVID-19. The recommendation for using remdesivir in patients with COVID-19 was based on the in vitro and in vivo activity of this drug against SARS-CoV-2. Methods: This was a prospective observational study conducted on a population of patients hospitalized for COVID-19. The primary endpoint of this study was the impact of remdesivir-containing therapy on 30-day mortality; the secondary endpoint was the impact of remdesivir-containing therapy on the need for high-flow oxygen therapy (HFNC), non-invasive ventilation (NIV), or mechanical ventilation. The data were analyzed after propensity score matching. Results: A total of 407 patients with SARS-CoV-2 pneumonia were consecutively enrolled. Out of these, 294 (72.2%) were treated with remdesivir and 113 (27.8%) were not. Overall, 61 patients (14.9%) were treated during hospitalization with HFNC, NIV, or mechanical ventilation, while 30-day mortality was observed in 21 patients (5.2%). Univariate analysis of patients treated with remdesivir or not showed no differences in 30-day mortality (4% vs. 6%, p = 0.411) in the two study groups. Cox regression analysis, after propensity score matching, showed that therapies, including remdesivir-containing therapy, were not statistically associated with 30-day survival or mortality. The Kaplan–Meier curves of 30-day survival in patients treated with remdesivir or not before (p = 0.24) and after (p = 0.88) propensity score matching showed no differences between the two study groups. Finally, patients treated with remdesivir or not showed the same need for HFNC/NIV or mechanical ventilation. Conclusions: This real-life experience of remdesivir use in hospitalized patients with COVID-19 was not associated with significant increases in rates of survival or reduced use of HFNC/NIV or mechanical ventilation compared with patients treated with other therapies not including remdesivir. MDPI 2021-08-24 /pmc/articles/PMC8432083/ /pubmed/34501233 http://dx.doi.org/10.3390/jcm10173784 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Russo, Alessandro Binetti, Erica Borrazzo, Cristian Cacciola, Elio Gentilini Battistini, Luigi Ceccarelli, Giancarlo Mastroianni, Claudio Maria d’Ettorre, Gabriella Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience |
title | Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience |
title_full | Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience |
title_fullStr | Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience |
title_full_unstemmed | Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience |
title_short | Efficacy of Remdesivir-Containing Therapy in Hospitalized COVID-19 Patients: A Prospective Clinical Experience |
title_sort | efficacy of remdesivir-containing therapy in hospitalized covid-19 patients: a prospective clinical experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432083/ https://www.ncbi.nlm.nih.gov/pubmed/34501233 http://dx.doi.org/10.3390/jcm10173784 |
work_keys_str_mv | AT russoalessandro efficacyofremdesivircontainingtherapyinhospitalizedcovid19patientsaprospectiveclinicalexperience AT binettierica efficacyofremdesivircontainingtherapyinhospitalizedcovid19patientsaprospectiveclinicalexperience AT borrazzocristian efficacyofremdesivircontainingtherapyinhospitalizedcovid19patientsaprospectiveclinicalexperience AT cacciolaeliogentilini efficacyofremdesivircontainingtherapyinhospitalizedcovid19patientsaprospectiveclinicalexperience AT battistiniluigi efficacyofremdesivircontainingtherapyinhospitalizedcovid19patientsaprospectiveclinicalexperience AT ceccarelligiancarlo efficacyofremdesivircontainingtherapyinhospitalizedcovid19patientsaprospectiveclinicalexperience AT mastroianniclaudiomaria efficacyofremdesivircontainingtherapyinhospitalizedcovid19patientsaprospectiveclinicalexperience AT dettorregabriella efficacyofremdesivircontainingtherapyinhospitalizedcovid19patientsaprospectiveclinicalexperience |